# Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

> **NCT06417775** · PHASE3 · RECRUITING · sponsor: **AbbVie** · enrollment: 496 (estimated)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Ubrogepant
- **DRUG:** Placebo for Ubrogepant

## Key facts

- **NCT ID:** NCT06417775
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-10
- **Primary completion:** 2027-06
- **Final completion:** 2027-09
- **Target enrollment:** 496 (ESTIMATED)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06417775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06417775, "Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT06417775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*